Nasus Pharma (NSRX) Total Debt (2024 - 2025)

Nasus Pharma's (NSRX) quarterly Total Debt came in at $2.6 million in Q2 2025, up 42.23% on a QoQ basis from $1.8 million in Q4 2024.

Nasus Pharma (NSRX) Total Debt (2024 - 2025) Analysis & Trends

Nasus Pharma (NSRX) has 2 years of Total Debt data on file, last reported at $2.6 million in Q2 2025.

Quarterly Total Debt changed N/A year-over-year to $2.6 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $2.6 million (changed N/A YoY) and the FY2024 annual result came in at $1.8 million, changed N/A from the prior year.
Total Debt grew to $2.6 million in Q2 2025, from $1.8 million in the prior quarter.
In the past five years, Total Debt ranged from a high of $2.6 million in Q2 2025 to a low of $1.8 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Johnson & Johnson	653.66 Bn	632.90 Bn	17.26 Bn	49.04 Bn
2	AbbVie	470.06 Bn	463.49 Bn	12.70 Bn	70.82 Bn
3	Merck	377.53 Bn	370.39 Bn	12.21 Bn	53.91 Bn
4	Novartis Ag	302.81 Bn	295.12 Bn	11.24 Bn	9.59 Bn
5	Astrazeneca	258.33 Bn	253.43 Bn	12.86 Bn	29.49 Bn
6	Amgen	237.17 Bn	223.18 Bn	7.24 Bn	62.75 Bn
7	Gilead Sciences	183.44 Bn	180.26 Bn	6.22 Bn	28.66 Bn
8	Pfizer	160.60 Bn	148.90 Bn	10.94 Bn	63.19 Bn
9	Gsk	106.09 Bn	101.92 Bn	8.24 Bn	-25.96 Bn
10	Nasus Pharma	29.28 Mn	29.28 Mn	-	-

Download Data

Date	Value
Jun 30, 2025	2.56 Mn
Dec 31, 2024	1.80 Mn